Advantages of total parathyroidectomy in patients with secondary hyperparathyroidism induced by end stage renal disease

甲状旁腺切除术 继发性甲状旁腺功能亢进 医学 多余的 自体移植 甲状旁腺功能亢进 外科 三期甲状旁腺功能亢进 泌尿科 内科学 移植 甲状旁腺激素 牙科
作者
Cristian Iorga,Cristina Raluca Iorga,Iuliana Andreiana,Iustinian Bengulescu,Traian Constantin,Victor Strâmbu
出处
期刊:Frontiers in Endocrinology [Frontiers Media]
卷期号:14 被引量:2
标识
DOI:10.3389/fendo.2023.1191914
摘要

Introduction Secondary hyperparathyroidism, as a result of chronic kidney disease could be treated medically or surgically. When pharmacotherapy fails, patients undergo surgery - parathyroidectomy, the curative treatment of secondary hyperparathyroidism (SHPT). There are currently 3 accepted surgical techniques, each with supporters or opponents – total parathyroidectomy, subtotal parathyroidectomy and parathyroidectomy with immediate autotransplantation. Methods In this paper we described our experience on a series of 160 consecutive patients diagnosed with secondary hyperparathyroidism who underwent surgery, in 27 cases it was totalization of the intervention (patients with previously performed subtotal parathyroidectomy or with supernumerary glands and SHPT recurrence). We routinely perform total parathyroidectomy, the method that we believe offers the best results. Results The group of patients was studied according to demographic criteria, paraclinical balance, clinical symptomatology, pre- and postoperative iPTH (intact parathormone) values, SHPT recurrence, number of reinterventions. In 31 cases we found gland ectopy and in 15 cases we discovered supernumerary parathyroids. A percentage of 96.24% of patients with total parathyroidectomy did not show recurrence. Discussions After analyzing the obtained results, our conclusion was that total parathyroidectomy is the intervention of choice for patients suffering from secondary hyperparathyroidism when pharmacotherapy fails in order to prevent recurrence of the disease and to correct the metabolic parameters.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
烟花应助asdfqwer采纳,获得10
刚刚
科研通AI5应助梦里吃早饭采纳,获得10
刚刚
加油的老赵完成签到,获得积分10
1秒前
活泼柜子发布了新的文献求助10
1秒前
为学日益发布了新的文献求助10
1秒前
小迷糊完成签到,获得积分10
1秒前
段段完成签到,获得积分10
1秒前
1秒前
共享精神应助栗子采纳,获得10
2秒前
星辰大海应助冬天该很好采纳,获得10
2秒前
qiqi发布了新的文献求助10
3秒前
4秒前
4秒前
pan完成签到,获得积分10
4秒前
大模型应助将将采纳,获得10
4秒前
4秒前
逝者如斯只是看着完成签到,获得积分10
4秒前
Cactus应助猛犸象冲冲冲采纳,获得10
5秒前
吕佳完成签到 ,获得积分10
6秒前
Wzx发布了新的文献求助10
6秒前
共享精神应助小谢采纳,获得10
6秒前
Chris完成签到,获得积分10
7秒前
8秒前
willa完成签到 ,获得积分10
8秒前
张远征发布了新的文献求助10
8秒前
沉静的傲柏完成签到,获得积分10
9秒前
猛犸象冲冲冲完成签到,获得积分10
9秒前
酷酷完成签到,获得积分10
9秒前
科研通AI5应助happy采纳,获得10
9秒前
快快毕业完成签到 ,获得积分10
9秒前
Singularity发布了新的文献求助10
10秒前
鱼鱼发布了新的文献求助10
10秒前
可爱的猪猪完成签到,获得积分10
10秒前
11秒前
barrychow完成签到,获得积分10
11秒前
霸道发布了新的文献求助10
11秒前
小白完成签到,获得积分10
11秒前
完美世界应助xupt唐僧采纳,获得10
11秒前
英俊的铭应助小泓采纳,获得10
11秒前
suan完成签到,获得积分10
12秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
CRC Handbook of Chemistry and Physics 104th edition 1000
Izeltabart tapatansine - AdisInsight 600
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 500
An International System for Human Cytogenomic Nomenclature (2024) 500
Introduction to Comparative Public Administration Administrative Systems and Reforms in Europe, Third Edition 3rd edition 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3767260
求助须知:如何正确求助?哪些是违规求助? 3311865
关于积分的说明 10160718
捐赠科研通 3027075
什么是DOI,文献DOI怎么找? 1661400
邀请新用户注册赠送积分活动 794031
科研通“疑难数据库(出版商)”最低求助积分说明 755955